Bicara Therapeutics Inc. Common Stock Cash Flow Conversion Efficiency
Bicara Therapeutics Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has a cash flow conversion efficiency ratio of -0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.21 Million) by net assets ($468.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bicara Therapeutics Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. This chart illustrates how Bicara Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bicara Therapeutics Inc. Common Stock (BCAX) stock price for real-time trading data and today's change.
Bicara Therapeutics Inc. Common Stock Cash Flow Conversion Ratio Explained
Bicara Therapeutics Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bicara Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Bicara Therapeutics Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sturm Ruger & Company Inc
NYSE:RGR
|
0.051x |
|
Beijing Telesound Electronics Co Ltd
SHE:003004
|
0.017x |
|
Wheels India Limited
NSE:WHEELS
|
0.411x |
|
BRASKEM PFD ADR/2 O.N.
F:BRD
|
0.055x |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
-0.014x |
|
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
|
0.046x |
|
Vaalco Energy Inc
NYSE:EGY
|
-0.114x |
|
Nilfisk Holding A/S
CO:NLFSK
|
0.061x |
Annual Cash Flow Conversion Efficiency for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. Review BCAX financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $401.45 Million | $-106.83 Million | -0.266x | -75.11% |
| 2024-12-31 | $491.88 Million | $-74.75 Million | -0.152x | +27.22% |
| 2023-12-31 | $218.51 Million | $-45.63 Million | -0.209x | -111.25% |
| 2022-12-31 | $-17.28 Million | $-32.08 Million | 1.856x | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more